New AAV Vectors for Safe and Efficient Expression of Lysosomal Enzymes in the CNS
- 詳細技術說明
- New AAV vectors that enable transgene expression at therapeutic levels for treatment of lysosomal and other disorders. These levels are achieved without the adverse events that arise due to secondary
- *Abstract
-
New AAV vectors that enable transgene expression at therapeutic levels for treatment of lysosomal and other disorders. These levels are achieved without the adverse events that arise due to secondary effects of AAV-mediated product delivery. This newly engineered regulatory element can apply broadly to circumvent adverse effects of AAV therapy.
- *IP Issue Date
- None
- *IP Type
- Other Patent
- 國家
- Not Available
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
